Publications by authors named "Courtney D DiNardo"

100Publications

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med 2020 08;383(7):617-629

From the Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., M.K.); the Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento (B.A.J.), the Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte (V. Pullarkat), and Genentech, South San Francisco (W.-J.H.) - all in California; the Section of Hematology and Oncology, Department of Medicine, University of Chicago Medicine, Chicago (M.J.T.), and AbbVie, North Chicago (Y.Z., J.P.) - both in Illinois; the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.S.G., A.L.); the Australian Centre for Blood Diseases, Alfred Hospital and Monash University, Melbourne, VIC (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H.D.); Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris and Université de Paris, Paris (P.F.); the Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna (E.K.); the Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels (V.H.); the Department of Medicine, McMaster University, Hamilton, ON, Canada (B.L.); the Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Barcelona (J.E.); the Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China (J.W.); the Department of Hematology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia (V. Pejsa); the Department of Clinic Subjects, University Hospital Ostrava-Poruba, Ostrava, Czech Republic (R.H.); Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki (K.P.); the Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary (A.I.); Hadassah Medical Center, Jerusalem (D.L.); the Clinic of Hematology, Department of Internal Medicine, University of Genoa, and San Martino Hospital IRCCS - both in Genoa, Italy (R.M.L.); the Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan (K.Y.); the Department of Internal Medicine, Seoul National University College of Medicine (S.-S.Y.), and the Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine (J.-H.J.) - both in Seoul, South Korea; the Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan (S.-P.Y.); the Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University, Samsun, Turkey (M.T.); and Abramson Cancer Center, University of Pennsylvania, Philadelphia (K.W.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2012971DOI Listing
August 2020

Venetoclax in acute myeloid leukemia - current and future directions.

Leuk Lymphoma 2020 06 7;61(6):1313-1322. Epub 2020 Feb 7.

Department of Leukemia, M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1719098DOI Listing
June 2020

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

Cancer Discov 2020 Apr 3;10(4):506-525. Epub 2020 Feb 3.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1011DOI Listing
April 2020

Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response.

Clin Lymphoma Myeloma Leuk 2020 02 26;20(2):e66-e75. Epub 2019 Nov 26.

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Canada; Leukemia Program, Department of Medical Oncology and Hematology, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.11.017DOI Listing
February 2020

Single-agent and combination biologics in acute myeloid leukemia.

Hematology Am Soc Hematol Educ Program 2019 12;2019(1):548-556

Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/hematology.2019000059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913489PMC
December 2019

Which novel agents hold the greatest promise in AML?

Best Pract Res Clin Haematol 2019 12 18;32(4):101106. Epub 2019 Oct 18.

Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd # 428, Houston, TX, 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.101106DOI Listing
December 2019

How I treat acute myeloid leukemia in the era of new drugs.

Blood 2020 01;135(2):85-96

Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001239DOI Listing
January 2020

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.

Ther Adv Hematol 2019 23;10:2040620719882822. Epub 2019 Oct 23.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719882822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811760PMC
October 2019

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Am J Hematol 2020 02 29;95(2):227-229. Epub 2019 Aug 29.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25610DOI Listing
February 2020

Hereditary myeloid malignancies.

Best Pract Res Clin Haematol 2019 06 3;32(2):163-176. Epub 2019 May 3.

Department of Leukemia, The University of Texas at MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.05.001DOI Listing
June 2019

Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres.

Pediatr Blood Cancer 2019 08 2;66(8):e27779. Epub 2019 May 2.

Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27779DOI Listing
August 2019

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

JCO Precis Oncol 2019 6;3. Epub 2019 Feb 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448807PMC
February 2019

Myeloid malignancies with somatic mutations can be associated with an immunodeficiency phenotype.

Leuk Lymphoma 2019 08 16;60(8):2025-2033. Epub 2019 Jan 16.

a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1551535DOI Listing
August 2019

Advances in patient care through increasingly individualized therapy.

Nat Rev Clin Oncol 2019 02;16(2):73-74

Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0156-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197511PMC
February 2019

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

Clin Lymphoma Myeloma Leuk 2018 12 21;18(12):769-772. Epub 2018 Oct 21.

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183142
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.10.007DOI Listing
December 2018

Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.

N Engl J Med 2018 09;379(12):1186

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1809507DOI Listing
September 2018

The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.

Ther Adv Hematol 2018 Jul 1;9(7):163-173. Epub 2018 Jun 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718777467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041864PMC
July 2018

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.

Cancers (Basel) 2018 Jun 6;10(6). Epub 2018 Jun 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025071PMC
June 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 06 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008108PMC
June 2018

The role of IDH mutations in acute myeloid leukemia.

Future Oncol 2018 Apr 15;14(10):979-993. Epub 2018 Mar 15.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0523DOI Listing
April 2018

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.

Curr Hematol Malig Rep 2017 12;12(6):537-546

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0418-6DOI Listing
December 2017